Updated:
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a biopharmaceutical company based in San Carlos, United States, founded in 2008. It develops a diverse portfolio of...
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a biopharmaceutical company based in San Carlos, United States, founded in 2008. It develops a diverse portfolio of well-characterized drugs for rare diseases. The company has secured $22.8 million in total funding.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Sector focus
Frequently asked questions
What caused Eiger BioPharmaceuticals to cease operations?
Eiger ran out of operating capital after its lead drug candidate failed in Phase 3 trials for hepatitis delta. The company was unable to find a buyer or raise additional financing, leading to a board decision in April 2024 to lay off staff and wind down operations (per the company's SEC filing, 2024).
Did Eiger ever have any approved drugs?
Eiger never obtained FDA approval for any of its pipeline candidates. Its most advanced program — a treatment for chronic hepatitis delta — failed in a pivotal Phase 3 trial in 2023, and other assets were in earlier stages (per the company's public press releases and clinical trial registry records).
Who were Eiger's major investors?
Eiger raised venture capital from institutional investors including OrbiMed, Frazier Healthcare Partners, and Deerfield Management in its earlier rounds, and later through public offerings on Nasdaq (per SEC filings). No single family office was identified as a principal backer.
How many employees did Eiger have at its peak?
The company reported approximately 30–35 full-time employees in 2023, according to its annual SEC filings. At its peak during the 2021–2022 trials, headcount may have been slightly higher but remained small relative to comparable biotech firms.
What drugs were in Eiger's pipeline?
Eiger's pipeline included lonafarnib (for hepatitis delta, failed Phase 3), peginterferon lambda (for hepatitis delta, phase 2), and several preclinical assets including an inhaled version of the antiviral favipiravir (public record). None advanced beyond phase 2 except lonafarnib.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: